Patient characteristics.
| Patients (male/female) | All, 20 (3/17) | Responders, 12 (2/10) | Nonresponders, 8 (1/7) | p |
|---|---|---|---|---|
| Age, yrs | 55.4 ± 3.15 (range 28–86) | 53.8 ± 3.96 (28–70) | 57.8 ± 5.38 (36–86) | NS |
| Disease duration, yrs | 5.90 ± 1.95 (1–31) | 3.08 ± 0.5 (1–6) | 10.1 ± 4.58 (1–31) | NS |
| Dosages of | ||||
| MTX, mg/wk | 7.83 ± 0.34 (6–12.5) | 7.50 ± 0.26 (6–8) | 8.31 ± 0.75 (6–12.5) | NS |
| Prednisolone, mg/day | 6.44 ± 0.44 (5–10) | 6.89 ± 0.69 (5–10) | 5.86 ± 0.45 (5–7.5) | NS |
| ESR, mm/h | 67.8 ± 8.18 (8–131) | 66.7 ± 9.48 (27–131) | 69.5 ± 15.5 (8–125) | NS |
| CRP, mg/dl | 3.74 ± 1.05 (0–19.9) | 3.75 ± 1.60 (0–19.9) | 3.71 ± 1.18 (0.2–8.4) | NS |
| TJC | 9.1 ± 1.5 (3–21) | 9.75 ± 1.70 (4–17) | 8.1 ± 2.8 (3–21) | NS |
| SJC | 4.2 ± 1.0 (2–15) | 7.2 ± 1.1 (2–15) | 5.9 ± 1.4 (2–12) | NS |
| DAS28, ESR-4 | 5.79 ± 0.29 (3.59–7.61) | 6.02 ± 0.31 (3.95–7.61) | 5.45 ± 0.55 (3.59–7.59) | NS |
| RF, IU/ml | 159.0 ± 46.0 (0–841.9) | 177.0 ± 68.2 (28.9–841.9) | 128.3 ± 49.0 (0–373.6) | NS |
| MMP-3, ng/ml | 92.1 ± 54.7 (63.8–792) | 385.1 ± 82.9 (92.1–792) | 254.0 ± 58.1 (63.8–494) | NS |
| Anti-CCP Ab, U/ml | 617.8 ± 303.5 (0–5950) | 920.3 ± 502.1 (28–5950) | 164.0 ± 53.1 (0–444) | NS |
MTX: methotrexate; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TJC: tender joint count; SJC: swollen joint count; DAS28: Disease Activity Score 28; RF: rheumatoid factor; MMP-3: matrix metalloproteinase-3; anti-CCP Ab: anti-cyclic citrullinated protein antibody; NS: not significant.